Effects of growth hormone administration in addition to gonadotrophins in normally ovulating women and polycystic ovary syndrome (PCO) patients.
Follicular fluid sex-steroids, insulin-like growth factor-I (IGF-I), IGF-I binding protein (IGF-I-BP) and epidermal growth factor were investigated in patients with polycystic ovaries and normally ovulating women, following ovulation induction with gonadotrophins or growth hormone plus gonadotrophins. Growth hormone supplementation enhanced the ovarian response to gonadotrophins, and significantly increased follicular fluid IGF-I in both groups, without affecting follicular fluid epidermal growth factor; growth hormone supplementation significantly decreased follicular fluid androstenedione in both groups.
Volpe
A
A
Department of Obstetrics and Gynaecology, University of Cagliari, Italy.
Artini
P G
PG
Barreca
A
A
Minuto
F
F
Coukos
G
G
Genazzani
A R
AR
D000328:Adult; D000735:Androstenedione / Q000096:biosynthesis; D002352:Carrier Proteins / Q000096:biosynthesis; D004357:Drug Synergism; D004815:Epidermal Growth Factor / Q000096:biosynthesis; D004958:Estradiol / Q000096:biosynthesis; D005260:Female; D015571:Follicular Fluid / Q000737:chemistry / Q000187:drug effects; D006062:Gonadotropins / Q000494:pharmacology*; D013006:Growth Hormone / Q000494:pharmacology*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D018970:Insulin-Like Growth Factor Binding Protein 1; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis; D010060:Ovulation / Q000187:drug effects*; D010062:Ovulation Induction / Q000379:methods; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011374:Progesterone / Q000096:biosynthesis
D002352:Carrier Proteins; D006062:Gonadotropins; D018970:Insulin-Like Growth Factor Binding Protein 1; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone